Last updated: September 7, 2026
Gefitinib is a mature, low-cost EGFR tyrosine kinase inhibitor with declining originator economics and expanding generic use. AstraZeneca’s Iressa franchise lost meaningful commercial value after generic entry, while demand continued in EGFR-mutated non-small-cell lung cancer, especially in China and other price-sensitive markets. Current value is concentrated in generic volume, regional distribution, and clinical niches rather than premium pricing.
What is gefitinib and where is it used?
Gefitinib is an oral, reversible epidermal growth factor receptor, or EGFR, tyrosine kinase inhibitor. It is used primarily for metastatic non-small-cell lung cancer, or NSCLC, with activating EGFR mutations.
The main target population includes patients with exon 19 deletions and exon 21 L858R substitutions. Gefitinib has also been used in other EGFR-mutated tumors in certain jurisdictions, but lung cancer remains its principal commercial market.
| Attribute |
Gefitinib |
| Originator brand |
Iressa |
| Originator |
AstraZeneca |
| Drug class |
EGFR tyrosine kinase inhibitor |
| Route |
Oral tablet |
| Common strength |
250 mg |
| Primary indication |
EGFR-mutated metastatic NSCLC |
| FDA approval |
2003; U.S. indication reapproved in 2015 |
| Key diagnostic requirement |
Confirmed EGFR mutation |
| Commercial status |
Generic and originator products in multiple markets |
| Principal competitors |
Osimertinib, erlotinib, afatinib, dacomitinib |
| Biosimilar exposure |
None; gefitinib is a small molecule |
The FDA’s 2015 approval limited use to patients whose tumors have specific EGFR mutations detected by an FDA-approved test. The approval was supported by data from the phase III IPASS study and subsequent analyses showing greater benefit in molecularly selected patients (U.S. Food and Drug Administration [FDA], 2015; Mok et al., 2009).
How large is the gefitinib market?
Gefitinib is a global product, but market value is fragmented and difficult to measure because AstraZeneca no longer reports it as a major standalone growth product and generic manufacturers generally do not disclose product-level revenue.
The commercial market has three tiers:
- High-volume, low-price generic markets, led by China and India.
- Regulated markets where generic competition has reduced prices.
- Smaller markets where Iressa remains available through local distribution or reimbursement channels.
The global value of gefitinib sales is substantially below the combined market for newer EGFR inhibitors. Osimertinib has displaced gefitinib as the preferred premium therapy in many first-line and adjuvant settings because of stronger central nervous system activity, longer progression-free survival, and activity against acquired T790M resistance.
China is the most important volume market
China remains strategically important because of its large EGFR-mutated NSCLC population and high mutation prevalence among Asian patients. Gefitinib entered the Chinese market through AstraZeneca and later competed with domestic products, including locally manufactured generics.
China’s National Medical Insurance Drug List has increased access to EGFR inhibitors through negotiated pricing. That mechanism expands patient volume but compresses net prices. Gefitinib benefits from broad physician familiarity, oral administration, and lower cost relative to osimertinib.
Domestic Chinese manufacturers have strengthened the price competition. Chinese companies with EGFR-TKI portfolios include Zhejiang Jiuzhou Pharmaceutical, Qilu Pharmaceutical, Hansoh Pharma, Jiangsu Hengrui, and other regional producers. Product availability and tender participation vary by province and procurement cycle.
India supports generic volume but not premium revenue
India has multiple gefitinib brands and generic suppliers. The market is driven by affordability, private-pay treatment, and oncology distribution networks. Indian products compete mainly on price and availability rather than differentiated clinical positioning.
Gefitinib is exposed to substitution by generic erlotinib and newer targeted therapies. Its commercial resilience comes from a lower acquisition cost and established use in EGFR-mutated disease.
What is the financial trajectory for gefitinib?
Gefitinib’s financial trajectory follows the standard lifecycle of an early targeted oncology product:
| Period |
Financial development |
| 2003-2010 |
Originator-led sales with strong pricing in selected markets |
| 2011-2015 |
Geographic expansion, indication refinement, and growing competition from erlotinib and afatinib |
| 2015-2017 |
U.S. regulatory reentry and generic competition |
| 2018-2021 |
Rapid erosion of originator economics; generic volume expands |
| 2022-present |
Mature, low-price market with regional demand and limited premium growth |
AstraZeneca’s public reporting has not provided a current, separately reported global revenue line for gefitinib. That prevents a precise current product-level revenue estimate. The economic direction is clear: Iressa has moved from a branded growth asset to a legacy product, while the total molecule market remains active through generics.
The main financial drivers are:
- EGFR mutation testing rates.
- Number of diagnosed metastatic NSCLC patients.
- National reimbursement decisions.
- Generic tender pricing.
- Availability of osimertinib.
- Treatment-line positioning.
- Local manufacturing capacity.
- Currency and procurement conditions in emerging markets.
Gefitinib’s unit volume can remain stable or grow even as market revenue declines. This occurs when lower-priced generics replace branded products and reimbursement expands patient access.
When did gefitinib lose exclusivity?
Gefitinib lost effective commercial exclusivity in the United States during the mid-2010s. AstraZeneca’s original U.S. Iressa authorization was withdrawn from the market in 2012 after the company stopped active commercialization, although the product remained available for certain existing patients. The FDA approved a new Iressa application in 2015 for EGFR-mutated metastatic NSCLC (FDA, 2015).
The U.S. generic market followed. Teva received FDA approval for a generic gefitinib product in 2017, according to FDA approval records and product listings. Other manufacturers subsequently entered or received approvals in various jurisdictions.
The important distinction is between:
- Patent expiry.
- FDA approval of a generic.
- Commercial launch.
- Originator withdrawal or reduced promotion.
- Loss of meaningful net pricing.
Gefitinib’s commercial exclusivity was effectively gone before the product ceased to have clinical value. The molecule continues to generate demand because generic entry lowers treatment cost.
What patents protect gefitinib?
Gefitinib’s principal composition-of-matter protection is expired in major markets. The original patent estate covered the quinazoline compound, pharmaceutical compositions, and use in cancer treatment. The key commercial barriers were concentrated in the United States, Europe, Japan, and other major regulatory markets.
Current patent risk is materially lower than for newer EGFR inhibitors. Remaining rights, where applicable, are more likely to involve:
- Specific formulations.
- Manufacturing processes.
- Polymorphs or solid-state forms.
- Combination therapy.
- Biomarker-defined treatment methods.
- Regional patent filings with limited enforceability.
These secondary rights generally do not recreate broad molecule-level exclusivity. A generic manufacturer can often design around process or formulation claims by using a different synthetic route, excipient system, or tablet process.
What is the Orange Book status of gefitinib?
The U.S. Orange Book historically included Iressa-related patents and exclusivity information. The practical U.S. status is now generic competition rather than active branded exclusivity. Gefitinib does not have the regulatory profile of a biologic, and the FDA does not apply the Purple Book biosimilar pathway.
For generic applicants, the relevant pathway is an abbreviated new drug application, or ANDA. Applicants must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. They do not need to repeat the full efficacy program required for the original approval.
Were there Paragraph IV challenges to gefitinib?
Generic entry into the United States could involve Paragraph IV certifications against listed patents. A Paragraph IV certification asserts that a patent is invalid, unenforceable, or not infringed.
Public commercial importance shifted away from Paragraph IV litigation once broad patent protection expired and the reference product became commercially mature. Gefitinib has not generated the continuing, high-value patent litigation seen with blockbuster products such as osimertinib, pembrolizumab, or lenalidomide.
The main litigation risk for a generic applicant has historically involved:
- Certification against remaining Orange Book patents.
- A 30-month stay following a timely patent-infringement action.
- Formulation or manufacturing patents.
- Product labeling and method-of-use issues.
The residual litigation exposure is limited compared with the exposure before generic launch.
What formulation and method-of-use patents protect gefitinib?
Gefitinib formulation protection is weaker than the patent position for extended-release products, inhaled systems, depot injections, or complex biologics. The commercial dosage form is a conventional oral tablet, which limits opportunities for durable formulation differentiation.
Potential secondary claim areas include:
- Tablet composition.
- Particle size.
- Dissolution characteristics.
- Stability.
- Manufacturing intermediates.
- EGFR mutation-selected treatment.
- Combination therapy with chemotherapy or other targeted agents.
Method-of-use patents can be commercially relevant if they cover a patient subset that remains reimbursed and clinically important. Their value is constrained by the requirement for accurate labeling, enforceability, and the ability to prevent off-label use. Generic manufacturers may seek a skinny label that omits patented uses where permitted by applicable law.
How does gefitinib compare with competing EGFR inhibitors?
| Drug |
Main commercial position |
Relative strength against gefitinib |
| Osimertinib |
Premium first-line and adjuvant EGFR therapy |
Superior CNS penetration and broader lifecycle value |
| Erlotinib |
Mature generic EGFR inhibitor |
Similar generic economics; different tolerability and dosing considerations |
| Afatinib |
Irreversible EGFR-family inhibitor |
More durable pathway inhibition but greater toxicity concerns |
| Dacomitinib |
Irreversible EGFR-family inhibitor |
Limited by tolerability and narrower commercial adoption |
| Gefitinib |
Low-cost, established first-generation therapy |
Strong affordability; weaker lifecycle and CNS profile |
Osimertinib is the most important competitive threat. It has become the preferred therapy in many treatment guidelines because it addresses common sensitizing EGFR mutations and has activity against central nervous system metastases. The FLAURA trial showed superior progression-free and overall survival for osimertinib compared with first-generation EGFR inhibitors, including gefitinib and erlotinib (Soria et al., 2018; Ramalingam et al., 2020).
Gefitinib remains competitive where price is the decisive factor, where osimertinib reimbursement is restricted, or where local treatment guidelines continue to recognize first-generation EGFR inhibitors.
Which companies are challenging or replacing gefitinib?
Competition is no longer limited to direct generic manufacturers. Gefitinib faces three distinct groups:
Generic manufacturers
Generic competition is strongest in China, India, and other cost-sensitive markets. Suppliers compete through tender pricing, regulatory approvals, oncology sales networks, and local manufacturing.
Branded targeted-therapy companies
AstraZeneca’s own osimertinib franchise has displaced part of the Iressa market. Boehringer Ingelheim’s afatinib, Roche’s erlotinib legacy franchise, and Pfizer’s dacomitinib have also competed for EGFR-mutated NSCLC patients.
Domestic Chinese oncology companies
Chinese drugmakers increasingly compete with imported products through national reimbursement negotiations, local clinical evidence, and provincial procurement. Their role reduces the pricing power of multinational suppliers and increases the probability of continuing price erosion.
What generic launch scenarios exist for gefitinib?
The likely commercial scenarios are:
| Scenario |
Market outcome |
| Low-cost generic expansion |
Volume increases while net price falls |
| Osimertinib reimbursement expansion |
Gefitinib loses first-line share in affluent and insured markets |
| Restricted access to newer agents |
Gefitinib retains volume in public hospitals and emerging markets |
| Procurement consolidation |
Fewer suppliers win tenders, increasing price pressure |
| Diagnostic expansion |
More EGFR-positive patients are identified, supporting unit demand |
| Originator discontinuation |
Generic products become the principal supply source |
The most likely base case is stable or modestly growing global volume with declining revenue per patient. Gefitinib is unlikely to regain premium pricing without a new formulation, combination indication, or materially differentiated clinical use.
What biosimilar risk exists for gefitinib?
There is no biosimilar risk because gefitinib is a chemically synthesized small molecule. The relevant threat is generic substitution under ANDA or equivalent national pathways.
This distinction matters commercially. Generic applicants face bioequivalence and pharmaceutical-equivalence requirements, not the complex comparability, immunogenicity, and manufacturing controls applicable to biologics.
How strong is the gefitinib patent estate?
The patent estate is weak for broad commercial protection and moderate for residual technical protection.
| Patent category |
Current strength |
| Composition of matter |
Expired in major markets |
| Core therapeutic use |
Expired or commercially weak |
| Conventional tablet |
Limited residual value |
| Manufacturing process |
Potentially relevant regionally |
| Polymorph or solid-state claims |
Narrow and design-around risk |
| Biomarker-selected use |
Potentially relevant but difficult to enforce broadly |
| Combination therapy |
Depends on claim scope and jurisdiction |
Gefitinib’s principal barrier is no longer intellectual property. The principal barriers are regulatory approval, quality manufacturing, supply reliability, tender access, physician familiarity, and EGFR diagnostic coverage.
What manufacturing and geographic barriers affect gefitinib?
Manufacturing is technically less complex than for biologic oncology products, but quality failures can disrupt supply. The critical operating requirements include:
- Consistent active pharmaceutical ingredient supply.
- Control of impurities and residual solvents.
- Tablet stability.
- Bioequivalence across production sites.
- Compliance with current good manufacturing practice.
- Reliable packaging and distribution.
Geographic protection is fragmented. Patent expiry and regulatory approvals vary by country, while procurement rules can determine commercial access even after legal exclusivity ends. China and India are central production and demand markets. Japan, South Korea, Southeast Asia, Latin America, and parts of the Middle East and Africa provide additional generic demand.
What is the outlook for gefitinib revenue?
Gefitinib revenue is likely to remain in long-term structural decline at the branded level and remain stable to moderately positive at the generic-volume level.
AstraZeneca’s economic exposure is limited because the company’s oncology growth is concentrated in newer products, including Tagrisso, Imfinzi, Enhertu, and other targeted therapies. Gefitinib is strategically more relevant as a legacy product and market-access reference than as a material current growth driver.
The molecule’s residual value is strongest where:
- EGFR mutation prevalence is high.
- Patients pay out of pocket.
- National reimbursement excludes or limits osimertinib.
- Generic prices are materially below newer agents.
- Physicians value long clinical experience.
- Oral oncology access is expanding.
Key Takeaways
- Gefitinib is a mature EGFR inhibitor with broad generic availability.
- AstraZeneca’s Iressa franchise has lost commercial exclusivity and is no longer a major growth asset.
- Generic entry has reduced price but expanded access and preserved patient volume.
- China and India are the most important markets for ongoing generic demand.
- Osimertinib is the principal clinical and commercial replacement in higher-value markets.
- Broad composition-of-matter protection has expired; remaining patent value is narrow and jurisdiction-specific.
- Gefitinib has no biosimilar risk because it is a small-molecule drug.
- The likely financial pattern is declining revenue per patient with stable or increasing low-price unit volume.
- Manufacturing quality, diagnostics, reimbursement, and procurement are more important than patent barriers in the current market.
FAQs
Is gefitinib still approved by the FDA?
Yes. The FDA approved gefitinib for metastatic NSCLC with specified EGFR mutations. Use requires molecular testing to identify an eligible tumor profile (FDA, 2015).
Is gefitinib cheaper than osimertinib?
Generic gefitinib is generally substantially cheaper than branded or patent-protected osimertinib. Actual net pricing depends on country, reimbursement status, procurement contracts, and pharmacy channel.
Can generic gefitinib be substituted for Iressa?
In markets where an approved generic is therapeutically equivalent to the reference product, pharmacy substitution may be permitted under local law. Substitution rules differ by jurisdiction.
Does gefitinib treat EGFR exon 20 insertion mutations?
Gefitinib is not generally considered an effective targeted treatment for EGFR exon 20 insertion mutations. Its established activity is concentrated in sensitizing mutations, particularly exon 19 deletions and exon 21 L858R substitutions.
Is AstraZeneca still financially dependent on gefitinib?
No. AstraZeneca’s current oncology economics are driven primarily by newer medicines. Gefitinib is a legacy product with limited standalone financial importance relative to the company’s modern oncology portfolio.
References
AstraZeneca. (2016). Annual report and form 20-F 2016. AstraZeneca PLC.
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.-J., Chewaskulyong, B., Jiang, H., Duffield, E. L., Watkins, C. L., Armour, A. A., & Fukuoka, M. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 361(10), 947-957. https://doi.org/10.1056/NEJMoa0810699
Ramalingam, S. S., Van Schil, P. E., et al. (2020). Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. New England Journal of Medicine, 382(1), 41-50. https://doi.org/10.1056/NEJMoa1913662
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reung le, W., Chewaskulyong, B., Lee, K. H., Dechorgnat, C., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Nakagawa, K., Cho, B. C., Hirashima, T., Takeda, K., Hotta, K., Fukuoka, M., van der Wekken, A. J., van den Heuvel, M. M., ... Ramalingam, S. S. (2018). Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. New England Journal of Medicine, 378(2), 113-125. https://doi.org/10.1056/NEJMoa1713137
U.S. Food and Drug Administration. (2015). FDA approves gefitinib for metastatic non-small cell lung cancer. https://www.fda.gov
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
